Overview
ORYL Photonics develops laser-based instruments for measuring solubility and aggregation of drug molecules and APIs in life sciences and pharma. Their patented light scattering technology, including the ORYL F1 platform, enables rapid, accurate, high-throughput analysis using minimal sample quantities. This Swiss EPFL spin-off supports R&D by reducing time and costs in formulation optimization.
Frequently asked questions
- What instruments does ORYL Photonics offer for pharma R&D?
- ORYL Photonics offers the ORYL F1, an automated laser-based platform for ultrafast measurement of solubility and aggregation of drug molecules and APIs using minimal quantities.
- What technology powers ORYL Photonics' solutions?
- Their patented Solvent Redistribution method uses high-efficiency second harmonic light scattering from femtosecond lasers for sensitive, accurate results with low sample consumption.
- Where is ORYL Photonics located and what is their background?
- ORYL Photonics is a Swiss company founded in 2020 as an EPFL spin-off, based in Epalinges, Switzerland, focused on life sciences applications.